Inactive Instrument

TearLab Corporation

Equities

Medical Equipment, Supplies & Distribution

TearLab Corporation Provides Preliminarily Revenue Guidance for the First Quarter 2016; Reaffirms Revenue Guidance for the Full Year 2016

April 21, 2016 at 12:58 am

TearLab Corporation provided preliminarily revenue guidance for the first quarter 2016. For the quarter, the company estimates that total revenue
will be approximately $6.8 million, reflecting an increase of 25% from the first quarter of 2015.

The company continues to expect annual revenue growth of 15% - 20% for the full year 2016.

Latest news about TearLab Corporation

TearLab Corporation Announces Board Appointments	09/12/21	CI
TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	09/12/21	CI
Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	09/11/21	CI
MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	16/09/21	CI
TearLab Appoints Adam Szaronos as Chief Commercial Officer	28/07/20	CI
Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	08/07/20	CI
TearLab Corporation to Seek Acquisitions	08/07/20	CI
Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	26/06/20	CI
TearLab Corporation Announces Board Appointments	11/05/20	CI
Tearlab Mulls Inorganic Growth Opportunities	11/05/20	CI
TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	10/05/20	CI
Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	10/05/20	CI
TearLab Corporation Resubmits 510(k) for U.S. FDA Clearance of the TearLab Discovery™ MMP-9 Test	22/04/20	CI
TearLab Corporation Announces Amendment to Loan Agreement	07/04/20	CI
TearLab Corporation Auditor Raises 'Going Concern' Doubt	05/03/20	CI
Tearlab Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	05/03/20	CI
Tearlab Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	08/11/19	CI
TearLab Corporation Enters into an Amendment to Its Term Loan Agreement	08/10/19	CI
Tearlab Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	08/08/19	CI
Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2019	10/05/19	CI
TearLab Corporation Auditor Raises 'Going Concern' Doubt	21/03/19	CI
Tearlab Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	21/03/19	CI
TearLab Corporation Announces Amendment to Loan Agreement	13/11/18	CI
Tearlab Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	07/11/18	CI
Tearlab Provides Update on 510(k) for U.S. FDA Clearance of Discovery MMP-9 Test	11/10/18	CI

Chart TearLab Corporation

Duration

Period

More charts

Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Glasses, Spectacles & Contact Lenses

	1st Jan change	Capi.
ALCON INC.	+22.39%	43.96B
THE COOPER COMPANIES, INC.	-0.30%	18.75B
AUTEK CHINA INC.	-20.50%	2.22B
WARBY PARKER INC.	+25.60%	2.11B
PEGAVISION CORPORATION	+19.17%	1.13B
MINGYUE OPTICAL LENS CO.,LTD.	-38.32%	716M
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	-10.65%	645M
MENICON CO., LTD.	-44.53%	632M
SHANGHAI CONANT OPTICAL CO., LTD.	+57.22%	606M

Glasses, Spectacles & Contact Lenses